- Université de Montréal Faculty of Medicine, Montreal, Quebec, Canada – MD
- Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montréal, Québec – Residency in Internal Medicine
- New England Medical Center Hospital, Tufts University – Fellowship in Hematology/Oncology
- St-Jude Children’s Research Hospital – Post-doctoral scientific research fellowship, Gene Therapy
Dr. Galipeau is a faculty member in the Division of Hematology, Oncology and Palliative Care within the Department of Medicine. Before being appointed the Don and Marilyn Anderson Professor of Oncology within the Department of Medicine and UW Carbone Cancer Center, Dr. Galipeau was a Professor of Hematology and Oncology and Director of the Emory Personalized Immunotherapy Center at Emory University in Atlanta, Georgia. Dr. Galipeau is also the Associate Dean for Therapeutics Discovery and Development at UWSMPH and the director of the University of Wisconsin Advanced Cell Therapy Program. The mission of this program is to develop personalized cell therapies for immune and malignant disorders and to promote and deploy first-in-human clinical trials of UW-Madison cell therapy innovations to improve outcomes for children and adults.
Dr. Galipeau is a board-certified Hematologist with an active clinical practice in consultative benign hematology.
View Dr. Galipeau's Publications
Dr. Galipeau has initiated and developed an NIH-funded research program in the study and use of mesenchymal stromal cells as an immunotherapy of catastrophic illnesses including cancer and immune disease. He is an internationally recognized expert in translational development of cell therapies and the sponsor of a series of FDA-sanctioned clinical trials examining the use of autologous marrow-derived mesenchymal stromal cells for immune disorders, including Crohn’s disease and graft vs host disease.